Recent Updates
Recently added Catalysts
RGEN Positive Sentiment

Repligen Corporation to Present at Evercore Healthcare Conference

Key Takeaway: Repligen Corporation will participate in the 8th Annual Evercore Healthcare Conference from December 2-4, 2025, in Coral Gables, Florida. CFO Jason Garland is scheduled for an analyst-led discussion on December 3 at 1:20 p.m. ET. A live webcast will be available on the company's Investor Relations website, with a replay option following the event.
Price reaction · baseline $171.76 (2025-11-25 close) · hit pre-market · clean, no other RGEN news in the window
day 0 close · peak
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Repligen Corporation is participating in a notable healthcare conference.
  • The event provides a platform for discussion on bioprocessing technology.
  • Live webcast allows broader access to the company's insights.

Full Press Release Details

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8thAnnual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on December 3rdat 1:20 p.m. ET.
A live webcast of the conference presentations will be accessible through Repligen’sInvestor Relationswebsite atwww.repligen.com, and will be available for replay for a limited period of time following the event.
About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are“inspiring advances in bioprocessing”for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website atwww.repligen.com, and follow us onLinkedIn.

Repligen Contact:Jacob JohnsonVP, Investor Relations781-419-0204investors@repligen.com

Frequently Asked Questions

When is Repligen participating in the conference?

Repligen will participate in the conference from December 2-4, 2025.

Who will represent Repligen at the conference?

CFO Jason Garland will represent Repligen during the analyst-led discussion.

How can I access the conference presentation?

The presentation will be available via a live webcast on Repligen's Investor Relations website.

What is the focus of Repligen Corporation?

Repligen focuses on developing bioprocessing technologies for manufacturing biological drugs.

Last updated: Nov 26, 2025